A Virtual Arm to Stop Smoking

Status Completed

Clinical Trial Summary

The investigators reported in a pilot study presented at last year's Cybertherapy Conference (Girard & Turcotte, 2007) that using an action-cue exposure strategy in virtual reality (ACE-VR; crushing virtual cigarettes) might be useful in the treatment of tobacco addiction.

The investigators are pursuing research in this area with a randomized control trial based on 90 smokers who will receive a brief psychosocial smoking cessation program (25 people are enrolled so far and we expect to finish the study before the conference). During the first four weeks of an eight-session psychoeducational and motivational program, all participants will be immersed in VR. During the immersions in VR, 45 of the participants will use a virtual arm to catch and crush virtual cigarettes. The other half of the sample will use the virtual arm to catch virtual fruits (control condition).

The smoking frequency, and abstinence, will be assessed with a daily diary and exhaled carbon monoxide tests (the CO2 tests will provide an objective confirmation of the abstinence reported in the diaries). The success the program will be compared based on the number of subjects who quitted or reduced their smoking frequency. The severity of addiction will be assessed with two questionnaires, the Fagerstrom and the Horn tests. Craving and withdrawal effects will be measured with the Minnesota Nicotine Withdrawal Scale (MNWS) and the Brief Questionnaire of Smoking Urges (QSU-Brief) at the baseline and at the visits from weeks 1 through 4, 6, 12 and at the end of the program. Before the VR immersion, the Immersive Tendencies Questionnaire will be administered and after each VR session participants will fill two questionnaires addressing presence and cybersickness. The comparative impact of both treatments will be tested with repeated measures ANOVAs (and planned contrasts) with sufficient power to detect medium effect sizes.

The main goal of our study is show that crushing virtual cigarettes can boost the impact of a behavioural program dedicated to cigarette addiction.

Clinical Trial Description

A detailed description is available, in French, by contacting stephane.bouchard@uqo.ca. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Cigarette Smoking

Clinical Trial Details

NCT number	NCT00639093
Study type	Interventional
Source	Universite du Quebec en Outaouais
Contact
Status	Completed
Phase	N/A
Start date	March 2008
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Recruiting	`NCT02422914` - Benefits of Tobacco Free Cigarette	N/A
Active, not recruiting	`NCT02629679` - Sports, Education and Consumption of Substances in Adolescents	N/A
Completed	`NCT02218281` - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation	N/A
Completed	`NCT02385227` - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes	N/A
Completed	`NCT01199380` - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms	Phase 2
Completed	`NCT01081119` - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth	Phase 2
Completed	`NCT00802919` - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors	Phase 4
Completed	`NCT00756704` - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department	N/A
Completed	`NCT01692353` - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers	N/A
Completed	`NCT00682474` - School Nurse-Delivered Smoking Cessation Intervention	Phase 2/Phase 3
Completed	`NCT05520775` - Semaglutide for Alcohol Use Disorder	Phase 2
Completed	`NCT03743532` - E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services	N/A
Terminated	`NCT03840694` - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior	N/A
Completed	`NCT06032793` - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.	N/A
Terminated	`NCT03326128` - High Dose Bupropion for Smoking Cessation - Pilot Study	Phase 2
Recruiting	`NCT03218670` - Your Health in On Click	N/A
Completed	`NCT02538042` - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.